{
    "nctId": "NCT00319618",
    "briefTitle": "Combination Weekly Taxotere\u2122 With Iressa\u2122 /Placebo in Metastatic Breast Cancer",
    "officialTitle": "A Randomised Phase II Study: Treatment With Daily p.o. Iressa\u2122 (ZD1839) or Placebo in Combination With Weekly IV Infusion of Docetaxel in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 66,
    "primaryOutcomeMeasure": "Objective tumour response (CR + PR) per RECIST criteria",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed mammary carcinoma\n\nExclusion Criteria:\n\n* prior taxane chemotherapy for metastatic disease or prior treatment with tyrosine kinase inhibitors inhibiting the EGF receptor.\n* Prior hormone treatment or one type of anthracycline based treatment regimen without taxane for metastatic disease is allowed prior to inclusion.\n* If the patient has been treated in the adjuvant or neoadjuvant setting with taxanes, inclusion is allowed when the first cycle of trial medication is started 12 months after the last course of adjuvant treatment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}